Estetrol (E4), the next generation hormone therapy (HT) for menopausal symptoms: phase 2b clinical trial results

      Introduction: Estetrol (E4) is a native estrogen with selective action in tissues. Previous data have demonstrated no effects on biomarkers of hemostasis, on triglycerides, and on breast cell stimulation. Its capacity to alleviate symptoms of menopause was tested here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect